Several studies have shown that the prevention of eIF2α dephosphorylation, either by genetic inactivation of PPP1R15A or by using phosphatase complex PPP1R15A/PP1c inhibitor such as guanabenz or Sephin1 (also named Icerguastat or IFB-088), reduces protein aggregates and improves motor neuron survival, motor performance, and survival in ALS animal models (Saxena et al, 2009; Tsaytler et al, 2011; Vaccaro et al, 2013; Jiang et al, 2014; Wang et al, 2014; Das et al, 2015). Here, EIF2A is linked to amyotrophic lateral sclerosis.